Owing to the aging population, increasing awareness of disease management, and continuous technological advancements, the global in vitro diagnostic reagents market is expected to grow from USD 69.25 billion in 2019 to USD 90.65 billion by 2023, with a CAGR of 6.2%.

A spokesperson from Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) recently responded to investors' questions about chemiluminescence at the 2022 Annual Investor Exchange.

On April 28, Lifotronic Technology Co., Ltd. released its 2022 annual report.

Oxford Nanopore Technologies plc and bioMérieux SA announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Eastern Money Choice data shows that as of April 13, 28 listed companies in the medical device category have disclosed their 2022 annual reports, of which 18 companies have achieved year-on-year growth in net profit, accounting for 64.29%.

Microorganisms are a group of tiny, invisible organisms that are mainly divided into fungi, actinomycetes, bacteria, spirochetes, rickettsiae, chlamydiae, mycoplasmas, and viruses. Different diseases correspond to different types of samples, including fluids obtained from patients' sputum, urine, blood, puncture fluid, cerebrospinal fluid, pus, and wound sites.

Digital health company Biostarks has announced new at-home longevity test kits that leverage the firm’s mass-spectrometry platform.

On March 14, 2023, Agilent Technologies announced the establishment of an innovation collaboration lab with Alta Scientific Co., Ltd.

Recently, Sansure and Singlera jointly established Jiangsu Yang Shengyuan Biotechnology Co., Ltd. with the registered capital of 10 million CNY at Yangzhou City.

Recently, Sansure Biotech Inc.'s new product launch conference and business partner recruitment conference was held in Changsha, China. More than 1,500 people participated in the conference and more than 120 dealers signed agreement.